Mentioned in ?
References in periodicals archive ?
BGE's credit profile as a regulated T&D utility is comparable with other EXC legacy utility subsidiaries Commonwealth Edison (ComEd; BBB+/Stable) and PECO Energy (PECO; BBB+/Stable).
Three ExC measurements were performed, the average being presented in mg of gallic acid equivalents (GAE) per 100 g of sample.
Prior to this, in 2011, Isis had received USD4.4m for its equity ownership of Excaliard from Pfizer's acquisition of Excaliard Pharmaceuticals and, excluding the USD1.25m, is eligible to receive an additional USD8.35m in contingent payments upon achievement of various milestones associated with the clinical and commercial progress of EXC 001, also referred to as PF-06473871.
The Rating Outlook for EXC, PECO, and BGE has been revised to Positive from Stable.
Novel drug company Isis Pharmaceuticals Inc (NasdaqGS:ISIS) said on Friday that it expects USD1.25m contingent payment from Pfizer Inc (NYSE:PFE) as the latter advances EXC 001 into a Phase 2 study.
Isis Pharmaceuticals Inc (NASDAQ:ISIS) will receive a part of the initial and milestone payments as it is an equity owner of Excaliard and has granted the company an exclusive worldwide licence for the development and sale of some antisense drugs, including EXC 001.
C10 ( STYLE AND PERFORMANCE/WH EXC 153CM: 1 Lucky Lucy, L Airey; 2 Norman, J Hunter.
A paragraph below this heading stated 'As of 1 December 2000, changes to BT's Light User Scheme mean that for every 10p that a bill is below GBP15.457 exc VAT, a rebate of 10.40p exc VAT is given.
The Positive Outlook for EXC is predicated on actual metrics post the PHI merger, which are stronger than originally anticipated, and continued strides in securing favorable rate outcomes in most PHI jurisdictions.
M2 EQUITYBITES-November 5, 2012-Isis receives USD1.25m as payment from Pfizer under EXC 001 development programme(C)2012 M2 COMMUNICATIONS
5 January 2010 - US biotechnology company Excaliard Pharmaceuticals Inc said today it has commenced three proof-of-concept Phase II trials of EXC 001, an antisense medicine that reduces fibrosis, for the amelioration of skin scarring and other fibrotic disorders.